ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
暂无分享，去创建一个
L. Magnani | A. Ballestrero | G. Pruneri | G. Viale | A. Vingiani | G. Bonizzi | A. Belfiore | L. Agnelli | M. Colleoni | G. Zoppoli | L. Ferrando | A. Garuti | E. Munzone | C. Vernieri | G. Dagrada | F. Ravera | Martina Dameri | Diana Ivanoiu | Luana Lippolis | Claudio Vernieri | Francesco Ravera